Low molecular weight heparin for thromboprophylaxis during caesarean section

Thrombosis Research

Volumn 96, Issue 4, 1999, Pages 317-322

  Bonnar, John ^a   Norris, Lucy A ^a   Greene, Richard ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

Author keywords

Caesarean section; Enoxaparin; LMWH; Thromboprophylaxis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; D DIMER; ENOXAPARIN; FIBRINOGEN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN;

ADULT; ARTICLE; CESAREAN SECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; THROMBOSIS PREVENTION;

ADULT; ANTIBODIES; BLOOD COAGULATION; CESAREAN SECTION; DELIVERY, OBSTETRIC; ENOXAPARIN; FACTOR XA; FEMALE; FETAL BLOOD; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032720363     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00117-6     Document Type: Article

References (24)

1. Bonnar J. Management of venous thrombosis in pregnancy and the puerperium. Poller L., Thomson J.J. Thrombosis and Its Management. 1993;47-63 Churchill Livingstone, London, Edinburgh, New York.
2. Royal College of Obstetricians and Gynaecology. Report on RCOG working party on prophylaxis against thromboembolism in gynaecology and obstetrics (1995).
3. Lowe G.D.O., Greer I.A., Cooke T.G., Dewar E.P., Evans M.J., Forbes C.D. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic risk factors THRIFT consensus group. Br Med J. 305:1992;567-574.
4. Lane D.A., Macgregor I.R., Michalski R., Kakkar V.V. Anticoagulant activity of four unfractionated and four fractionated heparins. Thromb Res. 12:1978;257-271.
5. Nelson-Piercy C., Letsky E.A., de Swiet M. Low-molecular-weight heparin for obstetric prophylaxis. Experience of sixty nine pregnancies in sixty-one women at high risk Am J Obstet Gynecol. 176:1997;1062-1068.
6. Food and Drug Administration (FDA). Reports of epidural or spinal haematomas with concurrent use of low molecular weight heparin and spinal/epidural anaesthesia or spinal puncture (Dec. 1997).
7. Teien A.N., Lie M. Evaluation of an amidolytic heparin assay method. increased sensitivity by adding purified antithrombin III Thromb Res. 10:1977;399-410.
8. Thompson J. Blood coagulation and haemostasis, a practical guide. 1980;Churchill Livingstone, Edinburgh, London, New York.
9. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung desfibrinogens. Acta Haematol. 17:1957;237-246.
10. Ødegård O.R., Lie M., Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res. 6:1975;287-289.
11. Koppert P.W., Hoegee-de Nobel E., Nieuwenhuisen W. A monoclonal antibody based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemost. 59:1988;310-315.
12. Boyle C. Fibrinolytic activators during normal pregnancy and pre-eclampsia. Thesis, University of Dublin, 1993.
13. Daly L. Fibrinolytic activity/inhibition and coagulation in normal pregnancy, pre-eclampsia and oral contraception. Thesis, University of Dublin, 1989.
14. Dahlman T.C., Hellgren M.S.E., Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol. 161:1989;420-425.
15. Melissari E., Parker C.J., Wilson N.V. Use of LMWH in pregnancy. Thromb Haemost. 6(8):1992;652-656.
16. Aich M., Priollet P., Roncato M., Housset E., Chassine J., Poissonier M.H. Low molecular weight heparin in venous thrombosis during pregnancy. Br J Haematol. 63(3):1986;605-606.
17. Sturridge F., De Swiet M. Thrombosis prophylaxis in obstetrics and gynaecology. Br J Obstet Gynecol. 101:1993;69-71.
18. Gillis S., Shushan A., Eldor A. Use of low molecular weight heparin for prophylaxis in pregnancy. Int J Obstet Gynecol. 39:1992;297-301.
19. Gibson J.L., Ekevall K., Walker I., Greer I.A. Puerperal thromboprophylaxis. comparison of the anti-Xa activity of enoxaparin and unfractionated heparin Br J Obstet Gynecol. 105:1998;795-797.
20. Bara L., Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand. 556(Suppl):1990;57-61.
21. Fejgin M.D., Louwood D.L. Low molecular weight heparins and their use in obstetrics and gynaecology. Obstet Gynaecol Surv. 49:1994;424-431.
22. Forestier F., Daffos F., Cappella-Pavlovsky M. Low molecular weight heparin (PK10169) does not seem to cross the placenta during the second trimester of pregnancy. Study by direct foetal blood sampling under ultrasound Thromb Res. 34:1984;557-560.
23. Andrew M., Ofuso F., Fernandez F., Jeffries A., Hirsch J., Mitchell L., Buchannan M.R. A low molecular weight heparin alters the fetal coagulation system in the pregnant sheep. Thromb Haemost. 55(3):1986;342-346.
24. Horlocker T.T., Heit J.A. Low molecular weight heparin. Biochemistry, pharmacology, perioperative prophylaxis regimens and guidelines for regional anaesthetic management Anaesth Analg. 85:1997;874-885.